Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Position Reduced by Perkins Capital Management Inc.

Perkins Capital Management Inc. lowered its position in shares of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK – Free Report) by 70.0% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 13,700 shares of the specialty pharmaceutical company’s stock after selling 32,000 shares during the quarter. Perkins […]

Related Keywords

Michael Bigham ,Randallb Brenner ,Renaissance Technologies ,News Ratings For Paratek Pharmaceuticals Daily ,Jefferies Financial Group ,Paratek Pharmaceuticals Company Profile ,Securities Exchange Commission ,Paratek Pharmaceuticals Inc ,Topco Ltd ,Perkins Capital Management Inc ,Paratek Pharmaceuticals Stock ,Paratek Pharmaceuticals ,Vanguard Group Inc ,Nasdaq ,Jpmorgan Chase Co ,Quarter For Paratek Pharmaceuticals ,Charles Schwab Investment Management Inc ,Perkins Capital Management ,Free Report ,Capital Management ,Schwab Investment Management ,Chairman Michael Bigham ,Exchange Commission ,Get Free Report ,Financial Group ,Visit Holdingschannel ,Paratek Pharmaceuticals Daily ,Nasdaq Prtk ,Prtk ,Medical ,89354m10 ,Sec Filings ,13f ,Hedge Fund Holdings ,Institutional Investor Holdings ,